Myriad Genetics (MYGN) Reports In-Line Q2 EPS, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. SPY
2. FLNC
3. CRM
4. GNRC
5. CRWV
6. LEN
7. NVDA
8. USO
9. LMT
10. AMZN

Go back to Myriad Genetics (MYGN) Reports In-Line Q2 EPS, Revenues Beat

Myriad Genetics Delivers 6% Sequential Revenue Growth; Company Continues to Execute Strategic Transformation Plan

February 23, 2021 4:05 PM EST

Highlights:

Revenue of $154.6 million up 6% sequentially in quarter ended Dec. 31, 2020GAAP Earnings per share (EPS) of ($0.59) and adjusted EPS of ($0.12) Despite COVID-19 headwinds, total test volumes increase 7% sequentially with stable pricingSigned in-network agreement with the majority of Anthem Blue Cross Blue Shield health plans, the second largest commercial payer in the United States, returning all Myriad products to in-network status

Paul J. Diaz, President and Chief Executive Officer:
In the midst... More